Skip to main content
Journal cover image

Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.

Publication ,  Journal Article
Wisdom, AJ; Mowery, YM; Riedel, RF; Kirsch, DG
Published in: Cancer
October 1, 2018

Soft tissue sarcomas (STS) are heterogeneous, mesenchymal malignancies with variable biologic behavior. The primary management for localized STS is surgical resection, which may be combined with neoadjuvant or adjuvant radiation therapy to increase the probability of achieving local control. Many patients with large, high-grade STS develop metastatic disease. Several clinical trials of immune checkpoint blockade for STS have produced promising responses in patients with metastatic disease. In this review, recent and ongoing clinical trials of immune checkpoint inhibition for STS are discussed. The authors explain the rationale for immune checkpoint inhibition and radiation therapy and highlight new studies testing this combination in the neoadjuvant setting for patients with high-risk STS. In addition, they describe novel combinations of immunotherapy with targeted therapies and chemotherapies being tested in the metastatic setting and discuss how these combinations have the potential to be integrated into adjuvant therapy in the future.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer

DOI

EISSN

1097-0142

Publication Date

October 1, 2018

Volume

124

Issue

19

Start / End Page

3819 / 3829

Location

United States

Related Subject Headings

  • Therapies, Investigational
  • Soft Tissue Neoplasms
  • Sarcoma
  • Rationalization
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Molecular Targeted Therapy
  • Medical Oncology
  • Immunotherapy
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wisdom, A. J., Mowery, Y. M., Riedel, R. F., & Kirsch, D. G. (2018). Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. Cancer, 124(19), 3819–3829. https://doi.org/10.1002/cncr.31517
Wisdom, Amy J., Yvonne M. Mowery, Richard F. Riedel, and David G. Kirsch. “Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.Cancer 124, no. 19 (October 1, 2018): 3819–29. https://doi.org/10.1002/cncr.31517.
Wisdom AJ, Mowery YM, Riedel RF, Kirsch DG. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. Cancer. 2018 Oct 1;124(19):3819–29.
Wisdom, Amy J., et al. “Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.Cancer, vol. 124, no. 19, Oct. 2018, pp. 3819–29. Pubmed, doi:10.1002/cncr.31517.
Wisdom AJ, Mowery YM, Riedel RF, Kirsch DG. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. Cancer. 2018 Oct 1;124(19):3819–3829.
Journal cover image

Published In

Cancer

DOI

EISSN

1097-0142

Publication Date

October 1, 2018

Volume

124

Issue

19

Start / End Page

3819 / 3829

Location

United States

Related Subject Headings

  • Therapies, Investigational
  • Soft Tissue Neoplasms
  • Sarcoma
  • Rationalization
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Molecular Targeted Therapy
  • Medical Oncology
  • Immunotherapy
  • Humans